Progress in lentiviral vector-mediated gene therapy for Alzheimer’s disease and Parkinson’s disease
Author:
Affiliation:

Clc Number:

Fund Project:

National Natural Science Foundation of China (No. 31571042), Natural Science Foundation of Beijing, China (No. 7202129), Science and Education Integration Special Fund Project of Chinese Academy of Sciences (Nos. KJRH2015-011, Y55201BY00).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common neurodegenerative diseases in human. The pathogenesis of AD and PD is complex, and the current drugs and surgical treatments have not successfully alleviated or terminated the progression of the diseases. The lentiviral vector (LV) is a retroviral vector. In recent years, LV mediated gene therapy has been a hotspot to study the mechanisms of human disease and clinical drug discovery. This review summarizes the recent progresses in the treatment of AD and PD by the application of LV, and offers a prospect for its application.

    Reference
    Related
    Cited by
Get Citation

许德润,刘力,郎明林. 慢病毒载体介导基因治疗阿尔茨海默症和帕金森症研究进展[J]. Chinese Journal of Biotechnology, 2020, 36(12): 2707-2718

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:March 31,2020
  • Revised:
  • Adopted:
  • Online: December 26,2020
  • Published:
Article QR Code